EP4061808A4 - Compositions and methods for treating disorders ameliorated by muscarinic receptor activation - Google Patents

Compositions and methods for treating disorders ameliorated by muscarinic receptor activation Download PDF

Info

Publication number
EP4061808A4
EP4061808A4 EP20888871.9A EP20888871A EP4061808A4 EP 4061808 A4 EP4061808 A4 EP 4061808A4 EP 20888871 A EP20888871 A EP 20888871A EP 4061808 A4 EP4061808 A4 EP 4061808A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
receptor activation
muscarinic receptor
treating disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20888871.9A
Other languages
German (de)
French (fr)
Other versions
EP4061808A1 (en
Inventor
Stephen Brannan
Andrew Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karuna Therapeutics Inc
Original Assignee
Karuna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karuna Therapeutics Inc filed Critical Karuna Therapeutics Inc
Publication of EP4061808A1 publication Critical patent/EP4061808A1/en
Publication of EP4061808A4 publication Critical patent/EP4061808A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP20888871.9A 2019-11-18 2020-11-17 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation Pending EP4061808A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962936837P 2019-11-18 2019-11-18
US202063030780P 2020-05-27 2020-05-27
PCT/US2020/060859 WO2021101875A1 (en) 2019-11-18 2020-11-17 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Publications (2)

Publication Number Publication Date
EP4061808A1 EP4061808A1 (en) 2022-09-28
EP4061808A4 true EP4061808A4 (en) 2023-12-20

Family

ID=75980892

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20888871.9A Pending EP4061808A4 (en) 2019-11-18 2020-11-17 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Country Status (5)

Country Link
EP (1) EP4061808A4 (en)
JP (1) JP2023503056A (en)
CN (1) CN115667235A (en)
CA (1) CA3161952A1 (en)
WO (1) WO2021101875A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114623C (en) 2018-09-28 2023-01-10 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170095465A1 (en) * 2009-07-22 2017-04-06 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
EP2456868A4 (en) * 2009-07-22 2013-11-06 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP2013516497A (en) * 2010-01-11 2013-05-13 ミスリィディオン，インク． COMPOUNDS AND COMPOSITIONS FOR COGNITIVE ENHANCEMENT, PRODUCTION METHODS, AND TREATMENT METHODS
CA3114623C (en) * 2018-09-28 2023-01-10 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170095465A1 (en) * 2009-07-22 2017-04-06 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"ACNP 57Annual Meeting: Poster Session I", NEUROPSYCHOPHARMACOLOGY, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 43, no. Suppl 1, 1 December 2018 (2018-12-01), pages 77 - 227, XP037114788, ISSN: 0893-133X, [retrieved on 20181206], DOI: 10.1038/S41386-018-0266-7 *
See also references of WO2021101875A1 *

Also Published As

Publication number Publication date
CA3161952A1 (en) 2021-05-27
EP4061808A1 (en) 2022-09-28
CN115667235A (en) 2023-01-31
JP2023503056A (en) 2023-01-26
WO2021101875A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
EP3856182A4 (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
AU2018242623B2 (en) Compounds and compositions for treating hematological disorders
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
EP2456868A4 (en) Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3999110A4 (en) Compositions and methods for treating autoimmune disorders
WO2009120810A3 (en) Neurodegenerative disorders
WO2008021375A3 (en) Modulators of muscarinic receptors
EP3973047A4 (en) Methods and compositions for treating liver disorders
EP3979985A4 (en) Compositions and methods for treating central nervous system disorders
WO2007100664A3 (en) Modulators of muscarinic receptors
EP3917620A4 (en) Compositions and methods for treating neurocognitive disorders
EP3917622A4 (en) Compositions and methods for treating anxiety-related disorders
IL275985A (en) Compositions and methods for treating retinal disorders
EP3917539A4 (en) Compositions and methods for treating neurocognitive disorders
EP3917623A4 (en) Compositions and methods for treating neurocognitive disorders
EP3911315A4 (en) Solid micronized melatonin composition
EP3829587A4 (en) Compositions and methods for treating brain-gut disorders
EP4061808A4 (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
AU2017257603A1 (en) Highly selective adenosine A3 receptor subtype agonsists for the prevention and treatment of neurodegenerative disorders
EP3939584A4 (en) Composition for preventing or treating obesity or lipid-related metabolic disorders
EP3735129A4 (en) Compositions and methods for treating neurological and other disorders
EP3697354A4 (en) Compositions and methods for treating eye disorders
WO2010083240A9 (en) Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
EP4076429A4 (en) Compositions and methods for treating neuromuscular disorders
EP3409130A4 (en) Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080197

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0401040000

Ipc: A61K0009160000

A4 Supplementary search report drawn up and despatched

Effective date: 20231121

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20231115BHEP

Ipc: A61P 25/18 20060101ALI20231115BHEP

Ipc: A61K 31/46 20060101ALI20231115BHEP

Ipc: A61K 31/4439 20060101ALI20231115BHEP

Ipc: C07D 405/14 20060101ALI20231115BHEP

Ipc: C07D 401/14 20060101ALI20231115BHEP

Ipc: C07D 401/04 20060101ALI20231115BHEP

Ipc: A61K 9/16 20060101AFI20231115BHEP